Edgewise Therapeutics (EWTX) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 155.6% versus a loss of 9.8%. Edgewise Therapeutics is the larger company by market cap ($4.26 billion vs $1.83 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | GPCR |
|---|---|---|
| Share price | $39.23 | $25.67 |
| Market cap | $4.26B | $1.83B |
| 1-day change | -0.86% | -3.79% |
| YTD return | +58.09% | -63.09% |
| 1-year return | +155.57% | -9.77% |
| 5-year return | +121.14% | — |
| EPS (TTM) | $-1.85 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-167.79M | $-141.20M |
| 52-week high | $48.51 | $94.90 |
| 52-week low | $14.25 | $25.09 |
| Distance from 52-week high | -19.13% | -72.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.13% | +312.08% |
| Average volume | 1.34M | 965.00K |
| Shares outstanding | 108.60M | 71.31M |
| Employees | 127 | 281 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edgewise Therapeutics is about 2.3 times larger than Structure Therapeutics by market value ($4.26B vs $1.83B).
- EWTX has outperformed GPCR by 165.3 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
EWTX vs GPCR FAQ
Which is bigger, Edgewise Therapeutics or Structure Therapeutics?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.26B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, EWTX or GPCR?
EWTX returned +155.57% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.